Pages that link to "Q50535464"
Jump to navigation
Jump to search
The following pages link to Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction (Q50535464):
Displaying 50 items.
- Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review (Q22242077) (← links)
- Kir6.2 is required for adaptation to stress (Q24538695) (← links)
- Cardiovascular safety of anti-diabetic drugs (Q26741082) (← links)
- Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation (Q26801343) (← links)
- Treating the elderly diabetic patient: special considerations (Q26995176) (← links)
- Impact of hypoglycemic agents on myocardial ischemic preconditioning (Q27014018) (← links)
- Glycemic control and cardiovascular disease: what's a doctor to do? (Q27024469) (← links)
- The Influence of Diabetes Mellitus in Myocardial Ischemic Preconditioning (Q28080349) (← links)
- Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus (Q28184813) (← links)
- Drugs for cardiovascular risk reduction in the diabetic patient (Q28195413) (← links)
- Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey (Q28198955) (← links)
- Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease (Q28343981) (← links)
- Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study (Q28534542) (← links)
- Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence (Q30234356) (← links)
- Effects of the I(K.ATP) blockers glibenclamide and HMR1883 on cardiac electrophysiology during ischemia and reperfusion (Q30321104) (← links)
- Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data (Q30530802) (← links)
- Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications (Q30817266) (← links)
- Are hypoglycaemia and other adverse effects similar among sulphonylureas? (Q31122704) (← links)
- Beating myocardium counteracts myogenic tone of coronary microvessels: involvement of ATP-sensitive potassium channels (Q33251446) (← links)
- Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus (Q33618721) (← links)
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (Q33880174) (← links)
- Comparative tolerability of sulphonylureas in diabetes mellitus (Q33903076) (← links)
- Diabetes mellitus and coronary heart disease--from prevention to intervention: Part II. (Q34099605) (← links)
- Nonhypoglycemic drug reactions of agents used to treat diabetes (Q34125408) (← links)
- Impaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events? (Q34180071) (← links)
- Clinical review of glimepiride (Q34240998) (← links)
- Pharmacological modulation, preclinical studies, and new clinical features of myocardial ischemic preconditioning. (Q34241310) (← links)
- Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore (Q34327908) (← links)
- Oral therapies for diabetic hyperglycemia (Q34451776) (← links)
- Clinical relevance of ischemic preconditioning (Q34523796) (← links)
- Cardiovascular safety profile of currently available diabetic drugs (Q34971736) (← links)
- Understanding myocardial ischemic preconditioning, and the implications for a role of adenosine catabolism (Q35072009) (← links)
- Cardiac NO signalling in the metabolic syndrome (Q35204828) (← links)
- Ischemia in type 2 diabetes: tissue selectivity of sulfonylureas and clinical implications (Q35206379) (← links)
- Ischemic heart disease in type 2 diabetes (Q35206383) (← links)
- Diabetes and cardiovascular disease: the road to cardioprotection. (Q35585114) (← links)
- Cardiovascular disease in patients who have diabetes (Q35585956) (← links)
- Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? (Q35607945) (← links)
- Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. (Q35672947) (← links)
- The role of sulphonylureas in the management of type 2 diabetes mellitus (Q35807254) (← links)
- Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study (Q35825313) (← links)
- Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy. (Q35847886) (← links)
- Pioglitazone and sulfonylureas: effectively treating type 2 diabetes (Q35987456) (← links)
- Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011. (Q36122492) (← links)
- Cardiac KATP channels in health and disease (Q36135766) (← links)
- Are sulfonylureas passé? (Q36640590) (← links)
- Where do conventional OADs stand (Q36701092) (← links)
- Hyperglycemia and perioperative glucose management (Q36810316) (← links)
- Role of Kir6.2 subunits of ATP-sensitive potassium channels in endotoxemia-induced cardiac dysfunction (Q36846892) (← links)
- Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? (Q37107490) (← links)